These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 24044798)

  • 1. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
    van Hezewijk M; Bastiaannet E; Putter H; Scholten AN; Liefers GJ; Rea D; Hasenburg A; Paridaens R; Hozumi Y; Markopoulos C; Seynaeve C; Jones SE; Marijnen CA; van de Velde CJ
    Radiother Oncol; 2013 Aug; 108(2):190-6. PubMed ID: 24044798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
    Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
    JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study.
    de Glas NA; Fontein DB; Bastiaannet E; Pijpe A; De Craen AJ; Liefers GJ; Nortier HJ; de Haes HJ; van de Velde CJ; van Leeuwen FE
    Cancer; 2014 Sep; 120(18):2847-54. PubMed ID: 24840230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
    Mamounas EP; Jeong JH; Wickerham DL; Smith RE; Ganz PA; Land SR; Eisen A; Fehrenbacher L; Farrar WB; Atkins JN; Pajon ER; Vogel VG; Kroener JF; Hutchins LF; Robidoux A; Hoehn JL; Ingle JN; Geyer CE; Costantino JP; Wolmark N
    J Clin Oncol; 2008 Apr; 26(12):1965-71. PubMed ID: 18332472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU
    Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
    Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
    J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery.
    Murphy CT; Li T; Wang LS; Obeid EI; Bleicher RJ; Eastwick G; Johnson ME; Hayes SB; Weiss SE; Anderson PR
    Clin Breast Cancer; 2015 Oct; 15(5):381-9. PubMed ID: 25861716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
    Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
    Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
    Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
    Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
    Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
    van Nes JG; Beex LV; Seynaeve C; Putter H; Sramek A; Lardenoije S; Duijm-de Carpentier M; Van Rongen I; Nortier JW; Zonderland HM; van de Velde CJ
    Acta Oncol; 2015 Mar; 54(3):349-60. PubMed ID: 25383451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Local relapse in young (< or = 40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results].
    Fodor J; Mózsa E; Zaka Z; Polgár C; Major T
    Magy Onkol; 2005; 49(3):203, 205-8. PubMed ID: 16249814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.
    Abdulkarim BS; Cuartero J; Hanson J; Deschênes J; Lesniak D; Sabri S
    J Clin Oncol; 2011 Jul; 29(21):2852-8. PubMed ID: 21670451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy.
    Min SY; Lee SJ; Shin KH; Park IH; Jung SY; Lee KS; Ro J; Lee S; Kim SW; Kim TH; Kang HS; Cho KH
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e697-705. PubMed ID: 21129858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection.
    Lupe K; Truong PT; Alexander C; Speers C; Tyldesley S
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e681-8. PubMed ID: 21300456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.